{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:10:27Z","timestamp":1791112227425,"version":"4.1.0"},"reference-count":69,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T00:00:00Z","timestamp":1272412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:italic>J. Neurochem.<\/jats:italic>(2010)<jats:bold>114<\/jats:bold>, 409\u2013511.<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p>Overactivity of striatal \u03b1\u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolepropionic acid (AMPA) glutamate receptors is implicated in the pathophysiology of<jats:sc>l<\/jats:sc>\u2010DOPA\u2010induced dyskinesia (LID) in Parkinson\u2019s disease (PD). In this study, we evaluated the behavioural and molecular effects of acute and chronic blockade of Ca<jats:sup>2+<\/jats:sup>\u2010permeable AMPA receptors in animal models of PD and LID. The acute effects of the Ca<jats:sup>2+<\/jats:sup>\u2010permeable AMPA receptor antagonist 1\u2010trimethylammonio\u20105\u2010(1\u2010adamantane\u2010methylammoniopentane) dibromide hydrobromide (IEM 1460) on abnormal involuntary movements (AIMs) in the 6\u2010hydroxydopamine (6\u2010OHDA)\u2010lesioned rat and LID in the MPTP\u2010lesioned non\u2010human primate were assessed. Subsequently, the effects of chronic treatment of 6\u2010OHDA\u2010lesioned rats with vehicle,<jats:sc>l<\/jats:sc>\u2010DOPA\/benserazide (6\/15\u2003mg\/kg, i.p.)\u2003+\u2003vehicle or<jats:sc>l<\/jats:sc>\u2010DOPA\u2003+\u2003IEM 1460 (3\u2003mg\/kg, i.p.) on behavioural and molecular correlates of priming for LID were evaluated. In the 6\u2010OHDA\u2010lesioned rat and MPTP\u2010lesioned non\u2010human primate, acute treatment with IEM 1460 (1\u20133\u2003mg\/kg) dose\u2010dependently reduced LID without adverse effects on motor performance. Chronic co\u2010treatment for 21\u2003days with IEM 1460 reduced the induction of AIMs by<jats:sc>l<\/jats:sc>\u2010DOPA in the 6\u2010OHDA\u2010lesioned rat without affecting peak rotarod performance, and attenuated AIMs score by 75% following<jats:sc>l<\/jats:sc>\u2010DOPA challenge (<jats:italic>p\u2003<\/jats:italic>&lt;\u20030.05). Chronic IEM 1460 treatment reversed<jats:sc>l<\/jats:sc>\u2010DOPA\u2010induced up\u2010regulation of pre\u2010proenkephalin\u2010A, and normalised pre\u2010proenkephalin\u2010B mRNA expression in the lateral striatum, indicating an inhibition of both behavioural and molecular correlates of priming. These data suggest that Ca<jats:sup>2+<\/jats:sup>\u2010permeable AMPA receptors are critically involved in both the induction and subsequent expression of LID, and represent a potential target for anti\u2010dyskinetic therapies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1471-4159.2010.06776.x","type":"journal-article","created":{"date-parts":[[2010,4,29]],"date-time":"2010-04-29T05:36:58Z","timestamp":1272519418000},"page":"499-511","source":"Crossref","is-referenced-by-count":94,"title":["Calcium\u2010permeable AMPA receptors are involved in the induction and expression of l\u2010DOPA\u2010induced dyskinesia in Parkinson\u2019s disease"],"prefix":"10.1111","volume":"114","author":[{"given":"Christopher","family":"Kobylecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Angela","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ravenscroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1999.0259"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0026-895X(25)08559-1","article-title":"Novel adamantane derivatives act as blockers of open ligand\u2010gated channels and as anticonvulsants","volume":"47","author":"Antonov S. M.","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-006-9177-9"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2006.10.020"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-01-00089.2000"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.08.017"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2004.02.011"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.02.007"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5023-03.2004"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20612"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(92)90120-3"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1992.tb00119.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/61.2.186"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00237-8"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10343"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.10.013"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.04124.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1998.00285.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00018-5"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196702162760703"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2005.12.009"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2007.01.013"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1997.6771"},{"key":"e_1_2_8_26_1","first-page":"S2","article-title":"The spectrum of levodopa\u2010induced dyskinesias","volume":"47","author":"Fahn S.","year":"2000","journal-title":"Ann. Neurol."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033447"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1148"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(88)91217-6"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6996"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00064-5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10542"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2166337"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-12-04686.2000"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.8.1589"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.07.005"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.7.1365"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/35016089"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00122-3"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-816x.2001.01843.x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.01.007"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.1997.655ba.x"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(01)00520-7"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03223.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.11.002"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04456.x"},{"key":"e_1_2_8_48_1","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","article-title":"A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson\u2019s disease","volume":"20","author":"Nash J. E.","year":"2000","journal-title":"J. Neurosci."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209532200"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2002.02275.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-14-05861.1999"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1040"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1678"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2003.09.001"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80144-0"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(96)01162-6"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1385-299X(97)00034-2"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00326-7"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0852-07.2007"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706233"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(97)00062-3"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-007-0195-7"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20739"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1699275"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017318"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20004"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1385\/MN:29:1:01"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.03.011"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.11.032"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2002.0499"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-4159.2010.06776.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-4159.2010.06776.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:17:41Z","timestamp":1740039461000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-4159.2010.06776.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1471-4159.2010.06776.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06776.x","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]}}}